Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
Total Net Revenue : $175.5 million for the full year 2023, up 31% from $134.0 million in 2022. Net Loss : Reduced to $78.0 million in 2023 from $108.2 million in 2022. Cash Position : $350.7 million in cash, cash equivalents, restricted cash, and investments as of December 31, 2023. Operational Savings : Expected annual savings of approximately $50 - $55 million from strategic restructuring. Share Repurchase Program : Up to $150 million, subject to regulatory approval in Canada. 2024 Revenue Guidance : Reaffirmed at $200 - $220 million. Warning! GuruFocus has detected 3 Warning Sign with AUPH. On February 15, 2024, Aurinia Pharmaceuticals Inc ( NASDAQ:AUPH ) released its 8-K filing , disclosing its financial results for the fourth quarter and full year of 2023. The biopharmaceutical company, known for developing LUPKYNIS (voclosporin) for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES), reported significant re
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthBusiness Wire
- Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going [Seeking Alpha]Seeking Alpha
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program [Yahoo! Finance]Yahoo! Finance
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramBusiness Wire
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference [Yahoo! Finance]Yahoo! Finance
AUPH
Earnings
- 2/15/24 - Miss
AUPH
Sec Filings
- 4/29/24 - Form 10-K/A
- 3/20/24 - Form SC
- 3/7/24 - Form 4
- AUPH's page on the SEC website